Terms: = Prostate cancer AND TFG, TF6, 10342, ENSG00000114354, Q92734
6 results:
1. Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective.
Varisli L; Tolan V; Cen JH; Vlahopoulos S; Cen O
Oncol Res; 2022; 30(3):137-155. PubMed ID: 37305018
[TBL] [Abstract] [Full Text] [Related]
2. Identification of phosphorylated proteins involved in the oncogenesis of prostate cancer via Pin1-proteomic analysis.
Endoh K; Nishi M; Ishiguro H; Uemura H; Miyagi Y; Aoki I; Hirano H; Kubota Y; Ryo A
Prostate; 2012 May; 72(6):626-37. PubMed ID: 21809350
[TBL] [Abstract] [Full Text] [Related]
3. Malignant cells, directors of the malignant process: role of transforming growth factor-beta.
Teicher BA
Cancer Metastasis Rev; 2001; 20(1-2):133-43. PubMed ID: 11831642
[TBL] [Abstract] [Full Text] [Related]
4. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.
Wolff JM; Fandel TH; Borchers H; Jakse G
Anticancer Res; 1999; 19(4A):2657-9. PubMed ID: 10470214
[TBL] [Abstract] [Full Text] [Related]
5. Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia.
Wolff JM; Fandel T; Borchers H; Brehmer B; Jakse G
Br J Urol; 1998 Mar; 81(3):403-5. PubMed ID: 9523660
[TBL] [Abstract] [Full Text] [Related]
6. Steroid-growth factor interaction in human prostate cancer. 1. Short-term effects of transforming growth factors on growth of human prostate cancer cells.
Carruba G; Leake RE; Rinaldi F; Chalmers D; Comito L; Sorci C; Pavone-Macaluso M; Castagnetta LA
Steroids; 1994 Jul; 59(7):412-20. PubMed ID: 7974525
[TBL] [Abstract] [Full Text] [Related]
